BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/16/2025 5:36:37 AM | Browse: 9 | Download: 28
 |
Received |
|
2024-11-01 08:53 |
|
Peer-Review Started |
|
2024-11-20 02:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-17 05:39 |
|
Revised |
|
2024-12-31 03:28 |
|
Second Decision |
|
2025-01-21 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-21 09:25 |
|
Articles in Press |
|
2025-01-21 09:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-27 01:54 |
|
Publish the Manuscript Online |
|
2025-04-16 05:36 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anna Terasawa, Kazuhiro Shimazu, Hiroshi Nanjo, Masatomo Miura and Hiroyuki Shibata |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| TAIHO Pharmaceutical |
AS2023A000122715 |
| Nippon Kayaku |
NKCS20230416001 |
|
| Corresponding Author |
Hiroyuki Shibata, MD, PhD, Professor, Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita 010-8543, Japan. hiroyuki@med.akita-u.ac.jp |
| Key Words |
Malignant meningioma; Curcumin; Diarylpentanoid curcumin analog; Hepatocellular growth factor; Nuclear factor kappa B; N-cadherin |
| Core Tip |
Malignant meningiomas have a poor prognosis, but drug development is limited due to their rarity. The curcumin analog GO-Y030 showed approximately 10-16 times stronger inhibitory effects than curcumin on IOMM-Lee and HKBMM cell lines, in vitro. Intraperitoneal administration of GO-Y030 also significantly inhibited the growth of malignant meningiomas, IOMM-Lee inoculated in nude mouse models. GO-Y030 significantly inhibited hepatocyte growth factor, nuclear factor kappa B, and N-cadherin, which contribute to epithelial-mesenchymal transition. |
| Publish Date |
2025-04-16 05:36 |
| Citation |
<p>Terasawa A, Shimazu K, Nanjo H, Miura M, Shibata H. Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models. <i>World J Exp Med</i> 2025; 15(2): 102897</p> |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i2/102897.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i2.102897 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
